Clinical trial Recruiting at 1 site Observational

Rare Disease Registry for Movement Disorders in Southern Anhui

Official title: Rare Disease Registry Database for Movement Disorders in Southern Anhui Province

Run by First Affiliated Hospital of Wannan Medical College · NCT07838883 · Data updated 2026-11-12

This project is creating a registry to collect information from adults with motor neuron diseases, spinocerebellar ataxias, hereditary muscular dystrophy, or hereditary spastic paraplegia in Southern Anhui.

More Hereditary Spastic Paraplegia trials

Quick facts

Study typeObservational
SexAll
Enrollment180 (estimated)
SponsorFirst Affiliated Hospital of Wannan Medical College
Academic / other
Locations1 site (Wuhu, Anhui)
StatusRecruiting
StartedSeptember 30, 2026
Main results expectedSeptember 2029
Study endsSeptember 2029
Registry record updatedOctober 23, 2026
Trial IDNCT07838883 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 19 years or older with a definitive diagnosis of ALS/MND, spinocerebellar ataxia, muscular dystrophy, or hereditary spastic paraplegia who can provide informed consent.

Probably not a fit

Patients who cannot provide informed consent or lack a definite diagnosis may not benefit directly from the registry.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry aims to document clinical features, diagnoses, and outcomes in patients with selected motor neuron and hereditary movement disorders. It collects data from eligible adults at a single center in Wuhu, Anhui, to better understand these rare conditions. The study addresses challenges in rare disease research such as small patient numbers and symptom diversity by systematically compiling patient information for future analyses. It does not involve an experimental treatment but focuses on data collection to support improved care and research planning. Participation is based on informed consent and specific diagnostic criteria.

Why it matters

Potential benefit: Participants may contribute to a better understanding of their condition and help build knowledge that could improve future diagnosis and care.

How similar studies have gone: Other rare-disease registries have shown value in improving understanding and guiding research, though specific outcomes vary by condition.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults aged 19 years or older who are capable of giving informed consent.
* Definitive diagnosis of one of the following diseases: (1) amyotrophic lateral sclerosis (diagnosed according to the revised El Escorial criteria, Awaji criteria, or Gold Coast criteria); (2) spinocerebellar ataxia; (3) muscular dystrophy; (4) hereditary spastic paraplegia.
* Others: primary lateral sclerosis, progressive muscular atrophy, ALS-FTD syndrome, progressive bulbar palsy, benign focal muscular atrophy, and other motor neuron diseases.

Exclusion Criteria:

* Patients with concomitant systemic diseases;
* Vulnerable research subjects: minors and patients with cognitive impairment;
* Participants from whom clinical information and human biological samples cannot be collected;
* Other patients judged by the investigators to be unsuitable for participation in the study.

Where it's running

  • First affiliated hospital of Wannan Medical University
    Wuhu, Anhui, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.